These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 21795305)

  • 1. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside.
    Choi HJ; Kim TY; Chung N; Yim JH; Kim WG; Kim JA; Kim WB; Shong YK
    J Endocrinol; 2011 Oct; 211(1):79-85. PubMed ID: 21795305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of 5-aminoimidazole-4-carboxamide-ribonucleoside was mediated by p38 mitogen activated protein kinase signaling pathway in FRO thyroid cancer cells.
    Kim WG; Choi HJ; Kim TY; Shong YK; Kim WB
    Korean J Intern Med; 2014 Jul; 29(4):474-81. PubMed ID: 25045295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.
    Baumann P; Mandl-Weber S; Emmerich B; Straka C; Schmidmaier R
    Exp Cell Res; 2007 Oct; 313(16):3592-603. PubMed ID: 17669398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
    Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AICAR inhibits proliferation and induced S-phase arrest, and promotes apoptosis in CaSki cells.
    Guan TJ; Qin FJ; Du JH; Geng L; Zhang YY; Li M
    Acta Pharmacol Sin; 2007 Dec; 28(12):1984-90. PubMed ID: 18031613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of CYP2E1 induces HepG2 cells death by the AMP kinase activator 5'-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).
    Zhuge J
    Cell Biol Toxicol; 2009 Jun; 25(3):253-63. PubMed ID: 18473182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase.
    Sauer H; Engel S; Milosevic N; Sharifpanah F; Wartenberg M
    Int J Oncol; 2012 Feb; 40(2):501-8. PubMed ID: 22002081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells.
    Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A
    J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF is a therapeutic target in aggressive thyroid carcinoma.
    Salvatore G; De Falco V; Salerno P; Nappi TC; Pepe S; Troncone G; Carlomagno F; Melillo RM; Wilhelm SM; Santoro M
    Clin Cancer Res; 2006 Mar; 12(5):1623-9. PubMed ID: 16533790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5'-AMP-Activated Protein Kinase Regulates Papillary (TPC-1 and BCPAP) Thyroid Cancer Cell Survival, Migration, Invasion, and Epithelial-to-Mesenchymal Transition.
    Cazarin JM; Coelho RG; Hecht F; Andrade BM; Carvalho DP
    Thyroid; 2016 Jul; 26(7):933-42. PubMed ID: 27121619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
    Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
    Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-aminoimidazole-4-carboxamide riboside enhances effect of ionizing radiation in PC3 prostate cancer cells.
    Isebaert SF; Swinnen JV; McBride WH; Begg AC; Haustermans KM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1515-23. PubMed ID: 21944462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
    Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
    BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.
    Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA
    Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.
    Al-Moujahed A; Nicolaou F; Brodowska K; Papakostas TD; Marmalidou A; Ksander BR; Miller JW; Gragoudas E; Vavvas DG
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(7):4175-85. PubMed ID: 24781943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy.
    Sengupta TK; Leclerc GM; Hsieh-Kinser TT; Leclerc GJ; Singh I; Barredo JC
    Mol Cancer; 2007 Jul; 6():46. PubMed ID: 17623090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.